ABEO Abeona Therapeutics Inc
- Pharmaceutical Preparation Manufacturing
15 minute delayed price. Price provided by IEX Cloud. The content contained therein is being provided to you for informational purposes only, does not constitute investment advice, financial advice, trading advice, or any other sort of advice, and does not constitute a recommendation by GoScour to buy, sell, or hold any security, financial product, or instrument referenced in the content. GoScour is not liable for any errors or delays in content, or for any actions taken in reliance on any content.
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company's portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical needs. Abeona's novel, next-generation AIM™ capsids have shown potential to improve tropism profiles for a variety of devastating diseases. Abeona's fully functional, gene and cell therapy GMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and commercial production of AAV-based gene therapies.